Exact Therapeutics AS

Exact Therapeutics AS Goodwill/Assets

Goodwill to Total Assets Ratio of Exact Therapeutics AS (EXTX.OL) as of Oct 25, 2026.

Goodwill/Assets

-

Last updated:

Goodwill to Total Assets Ratio of Exact Therapeutics AS is 2026 - . Goodwill to Total Assets Ratio of Exact Therapeutics AS was 2025 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exact Therapeutics AS Stock analysis

What does Exact Therapeutics AS do? Exact Therapeutics AS develops ACT sonoporation, a platform for ultrasound-mediated targeted drug enhancement to amplify therapeutic agents' clinical utility across cancer, infectious diseases, and neurological conditions. The company monetizes through research and development services for pharmaceutical partners seeking to enhance existing drug therapies with ultrasound targeting. Its primary customers are biopharmaceutical firms aiming to improve chemotherapy, immunotherapy, and other treatments. The firm's purpose centers on extending patient lives through targeted therapeutic enhancement using ultrasound and ACT formulation. Exact Therapeutics AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exact Therapeutics AS stock

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio Exact Therapeutics AS since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's Exact Therapeutics AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Exact Therapeutics AS

All Key Metrics — Exact Therapeutics AS